Claims
- 1. A compound having the structure:
- 2. A compound having the structure:
- 3. A compound having the structure:
- 4. A compound having the structure:
- 5. A compound having the structure:
- 6. A compound having the structure:
- 7. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497 and 500 are F, L and I, respectively.
- 8. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497, 498, 499, 500, 501 and 502 are L, W, D, W, P and F, respectively.
- 9. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497, 498, 499, 500, 501 and 502 are F, F, T, R, F, M and R, respectively.
- 10. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497, 498, 499, 500, 501 and 502 are F, P, H, P, G, W and L, respectively.
- 11. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497, 498, 499, 500, 501 and 502 are F, I, R, L, T, P and P, respectively.
- 12. A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 495, 497, 498, 499, 500, 501 and 502 are F, D, F, S, F, W and F, respectively.
- 13. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 3.
- 14. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 5.
- 15. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 7.
- 16. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 9.
- 17. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 11.
- 18. A polynucleotide that encodes an amino acid sequence comprising the amino acids of SEQ ID NO: 13.
- 19. A polynucleotide that encodes a peptide of any of claims 1 to 6.
- 20. An antibody that specifically recognizes and binds a compound of any of claims 1 to 6.
- 21. A method for inducing an immune response in a subject, comprising delivering an effective amount of a compound of any of claims 1 to 6 to the subject.
- 22. The method of claim 21, wherein the compound is delivered in the context of an MHC molecule.
- 23. The method of claim 22, wherein the MHC molecule presents the compound on the surface of an antigen presenting cell.
- 24. The method of claim 21, wherein the compound is delivered as a polynucleotide that encodes the compound.
- 25. A method of immunotherapy, comprising administering to a subject an effective amount of an antibody of claim 20.
- 26. An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents the compound of any of claims 1 to 6 in the context of an MHC molecule.
- 27. A method of adoptive immunotherapy, comprising administering an effective amount of the immune effector cell of claim 26.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S. application Ser. No.09/812,079 filed Mar. 19, 2001, now pending, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Serial Nos. 60/191,050 and 60/254,989, filed Mar. 21, 2000 and Dec. 12, 2000, respectively. The entire contents of these applications are hereby incorporated by reference into the present disclosure.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60191050 |
Mar 2000 |
US |
|
60254989 |
Dec 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09812079 |
Mar 2001 |
US |
Child |
10434982 |
May 2003 |
US |